Marshall Wace, LLP Apellis Pharmaceuticals, Inc. Put Options Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
337Shares Held
111MCall Options Held
1.26MPut Options Held
1.14M-
Wellington Management Group LLP Boston, MA15.1MShares$533 Million0.16% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.4MShares$402 Million19.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$393 Million7.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.51MShares$337 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$195 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.89B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...